CA2477808A1 - Methods of treating nerve entrapment syndromes - Google Patents

Methods of treating nerve entrapment syndromes Download PDF

Info

Publication number
CA2477808A1
CA2477808A1 CA002477808A CA2477808A CA2477808A1 CA 2477808 A1 CA2477808 A1 CA 2477808A1 CA 002477808 A CA002477808 A CA 002477808A CA 2477808 A CA2477808 A CA 2477808A CA 2477808 A1 CA2477808 A1 CA 2477808A1
Authority
CA
Canada
Prior art keywords
nerve
syndrome
patient
pain
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002477808A
Other languages
English (en)
French (fr)
Inventor
Christopher O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Solstice Neurosciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2477808A1 publication Critical patent/CA2477808A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002477808A 2002-03-01 2003-02-27 Methods of treating nerve entrapment syndromes Abandoned CA2477808A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36062802P 2002-03-01 2002-03-01
US60/360,628 2002-03-01
PCT/US2003/006233 WO2003073994A2 (en) 2002-03-01 2003-02-27 Methods of treating nerve entrapment syndromes

Publications (1)

Publication Number Publication Date
CA2477808A1 true CA2477808A1 (en) 2003-09-12

Family

ID=27788996

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002477808A Abandoned CA2477808A1 (en) 2002-03-01 2003-02-27 Methods of treating nerve entrapment syndromes

Country Status (7)

Country Link
US (2) US20030224019A1 (enExample)
EP (1) EP1487481A4 (enExample)
JP (1) JP2005524663A (enExample)
KR (1) KR20040094756A (enExample)
AU (2) AU2003212473A1 (enExample)
CA (1) CA2477808A1 (enExample)
WO (1) WO2003073994A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
AU2003212473A1 (en) * 2002-03-01 2003-09-16 Solstice Neurosciences, Inc. Methods of treating nerve entrapment syndromes
US7300412B2 (en) * 2002-05-10 2007-11-27 Hospital For Joint Diseases Methods for therapeutic treatment of carpal tunnel syndrome
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
KR100668570B1 (ko) * 2004-06-28 2007-01-16 입센 리미티드 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7897147B2 (en) 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
WO2011038015A1 (en) 2009-09-24 2011-03-31 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
WO2011123165A1 (en) 2010-03-31 2011-10-06 Toray Plastics (America), Inc. Biaxially oriented polyactic acid film with reduced noise level
US9101794B2 (en) 2010-09-19 2015-08-11 Thomas Alan Ferguson, JR. Piri-stretcher
USD703824S1 (en) 2010-09-19 2014-04-29 Thomas Alan Ferguson, JR. Leg stretching device
US9782617B2 (en) 2010-09-19 2017-10-10 Thomas Alan Ferguson, JR. Piri-stretcher system
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
JP6470678B2 (ja) 2012-04-13 2019-02-13 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド ニューロンの開口分泌を阻害する化合物（ｉｉ）
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
EP3470054B1 (en) 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US10561715B2 (en) * 2018-02-26 2020-02-18 Philip Andrew RADOVIC Plantar heel pain syndrome treatment
EP3825689A3 (en) 2018-11-29 2021-09-15 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
US12290301B1 (en) 2024-08-19 2025-05-06 Panacea Spine, LLC Percutaneous surgical treatment for piriformis syndrome

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) * 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
AU4646393A (en) * 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DK0758900T3 (da) * 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5562899A (en) * 1995-02-28 1996-10-08 Gerber; Allen Medical prevention of lacerations to the vagina and perineum
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
CA2369810C (en) * 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
AU2003212473A1 (en) * 2002-03-01 2003-09-16 Solstice Neurosciences, Inc. Methods of treating nerve entrapment syndromes

Also Published As

Publication number Publication date
JP2005524663A (ja) 2005-08-18
AU2003212473A1 (en) 2003-09-16
EP1487481A4 (en) 2005-11-23
US20080171065A1 (en) 2008-07-17
WO2003073994A2 (en) 2003-09-12
AU2009201770A1 (en) 2009-05-28
WO2003073994A3 (en) 2004-02-05
KR20040094756A (ko) 2004-11-10
EP1487481A2 (en) 2004-12-22
US20030224019A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
US20080171065A1 (en) Methods of Treating Nerve Entrapment Syndromes
Childers et al. Botulinum toxin type A use in piriformis muscle syndrome: a pilot study
US7255866B2 (en) Botulinum toxin therapy for fibromyalgia
Yoon et al. Low‐dose botulinum toxin type A for the treatment of refractory piriformis syndrome
JP4381477B2 (ja) 筋膜疼痛症候群の治療方法
Childers et al. Comparison of Two Injection Techniques Using Botulinum Toxin in Spastic Hemiplegia1
Yelnik et al. Drug treatments for spasticity
O’Brien et al. Spasticity after stroke: epidemiology and optimal treatment
Lam et al. Ultrasound and electrical stimulator-guided obturator nerve block with phenol in the treatment of hip adductor spasticity in long-term care patients: a randomized, triple blind, placebo controlled study
Wissel et al. Assessment, goal setting, and botulinum neurotoxin a therapy in the management of post-stroke spastic movement disorder: updated perspectives on best practice
Hidayati et al. Current diagnosis and management of carpal tunnel syndrome: A review
TW202112348A (zh) 中度至極重度眉間紋及眼角外紋之治療
Alter High-frequency ultrasound guidance for neurotoxin injections
Arens et al. Experience with botulinum toxin in the treatment of cerebral palsy
Reebye et al. Module 2: nonsurgical management of spasticity
Chang et al. Comparison of the therapeutic effects of intramuscular subscapularis and scapulothoracic bursa injections in patients with scapular pain: a randomized controlled trial
Aktürk et al. Functional outcomes following ultrasound-guided botulinum toxin type A injections to reduce spastic equinovarus in adult post-stroke patients
Huang et al. Efficacy analysis of ultrasound-guided local injection of botulinum toxin type A treatment with orthopedic joint brace in patients with cervical dystonia
Vaiman et al. Oxycodone and dexamethasone for pain management after tonsillectomy: a placebo-controlled EMG assessed clinical trial
Koh et al. Alcohol motor blocks: case series and a narrative review
Marvulli et al. Clinical onset of action of incobotulinum toxin a preparation
Kemp et al. Muscular fibrosis due to chronic intramuscular administration of narcotic analgesics
Sharma et al. Impact of Ultrasound-Guided Suprascapular Nerve Block in Stroke Survivors With Hemiplegic Shoulder Pain Undergoing Neurorehabilitation: A Retrospective Case Series
Smith et al. Other dermatologic uses of botulinum toxin
Raj Treatment algorithm overview: BoNT therapy for pain

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued